Rapidly reduce the level of new coronavirus in patients with innovative oral therapy Phase 2 clinical results are positive

On June 30, 2021, Atea Pharmaceuticals announced that its under-study oral antiviral drug AT-527 has obtained positive mid-term results in a phase 2 clinical trial for the treatment of hospitalized patients with mild/moderate COVID-19.

AT-527 is an oral purine nucleotide prodrug

The interim analysis of this randomized, double-blind, placebo-controlled, multicenter, global Phase 2 trial included data on 70 high-risk COVID-19 hospitalized patients, of which 62 patients’ data can be used for virological analysis and evaluation

▲AT-527 molecular structure (picture source: reference [2])

In addition, compared with the control group, the potent antiviral activity of AT-527 was also observed in patients with a baseline median viral load higher than 5.

The safety aspect is consistent with previous studies.

Note: The original text has been deleted

Reference materials:

[1] Atea's AT-527, an Oral Antiviral Drug Candidate, Reduces Viral Replication in Hospitalized Patients with COVID-19 in Phase 2 Interim Analysis.

[2] Roche partners with Atea on COVID-19 antiviral.